Table 5 Publications on acute toxicity of radiotherapy of the prostate bed with or without pelvic irradiation
Acute grade 1 | Acute grade 2 | Acute grade 3 | Acute grade 4 | ||||||
|---|---|---|---|---|---|---|---|---|---|
GI | GU | GI | GU | GI | GU | GI | GU | ||
Bellavita et al. [13] | 3D-CRT prostate bed 66.6 Gy | 48.9% (G1/2) | - | - | - | 1.1% | - | 0% | 0% |
Current trial | IMRT WPRT 51 Gy + boost prostate bed 68 Gy | 67.5% | 22.5% | 22.5% | 22.5% | 0% | 0% | 0% | 0% |
Alongi et al.[14] | IMRT WPRT 50.6 Gy + boost prostate bed 70–72.5 Gy | - | - | 3.3% | 6.6% | 0% | 0% | 0% | 0% |
Deville et al.[15] | IMRT WPRT 45 Gy Gy + boost prostate bed 70.2 Gy | 31% | 67% | 61% | 22% | 0% | 0% | 0% | 0% |
Alongi et al.[14] | 3D-CRT WPRT 50.1 Gy + boost prostate bed 72.1 Gy | - | - | 8.6% | 12.3% | 0% | 0% | 0% | 0% |
Aizer et al.[16] | 3D-CRT WPRT 45 Gy + IMRT boost prostate 75.6 Gy | 75% | 44.1% | 17.6% | 33.8% | 1.5% | 10.3% | 0% | 0% |
Roach et al.[4] | 3D-CRT WPRT 45 Gy + boost prostate 70.2 Gy | - | - | - | - | 2.6% (G3/4) | 3.9% (G3/4) | 0% | 0% |
Liu et al.[17] | 2D WPRT 45 Gy + boost prostate 72 Gy | 12.2% | 10.9% | 1.3% | 3.8% | 0.6% | 0.6% | 0% | - |